— Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need — — QRX003 lotion (4%) currently being ...

The Dermatology Division of the U.S. Food and Drug Administration has granted Fast Track designation to sonelokimab in moderate-to-severe palmoplantar pustulosis supported by positive results from the ...

The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by ...

With Fast Track designation, we believe this can support the acceleration of our Phase 3 program through earlier and more frequent FDA engagement, enabling faster addressing of development questions, ...

— QRX003 lotion (4%) currently being evaluated in two late-stage whole-body clinical trials for treatment of Netherton Syndrome — — Fast Track Designation follows Pediatric Rare Disease and Orphan ...

NASHVILLE, Tenn., Feb. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, announced today ...